A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

NCT00328549 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C
Anemia

Interventions

DRUG: Pegylated Interferon and Ribavirin

Sponsor

Ortho Biotech Products, L.P.